Cogent Biosciences
Developing precision therapies for genetically defined diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $400m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 565 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (778 %) | (84 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (855 %) | (46 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Cogent Biosciences is a biotechnology company focused on the discovery and development of innovative small molecule therapies targeting rare, genetically driven diseases. The company serves patients with unmet medical needs, particularly those suffering from conditions that have limited treatment options. Operating within the biopharmaceutical market, Cogent Biosciences employs a research-driven business model, leveraging its scientific expertise to advance drug candidates through clinical trials. Revenue is primarily generated through the development and potential commercialization of these therapies, as well as through strategic partnerships and collaborations. The company has a strong financial position, with a year-end cash reserve of $242.2 million, supporting its ongoing research and development activities. Key initiatives include three clinical trials for their lead candidate, CGT9486, set to commence this year.
Keywords: biotechnology, small molecule therapies, rare diseases, genetically driven, clinical trials, drug discovery, biopharmaceutical, research-driven, strategic partnerships, CGT9486.